Mehdi Gasmi, SVP, Pharmaceutical Development at Avalanche Biotechnologies, Inc. ([AAVL]), sold 500 shares at $39.86 ($20K) on 2015-06-15, disclosed to the SEC on 2015-06-17.
Scheduled sale ($20k) by SVP, Pharmaceutical Development under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| ADVM | SELL | 2020-06-18 | $563K | — | Filing → |
| ADVM | SELL | 2020-06-17 | $324K | — | Filing → |
| ADVM | SELL | 2020-05-22 | $100K | — | Filing → |